US2006275317A1PendingUtilityA1
Vaccine compositions for prevention of chronic and infectious diseases
Est. expiryDec 23, 2023(expired)· nominal 20-yr term from priority
Inventors:Francois-Xavier BerthetFrancesc Vayreda CasadevallMaria Cruz Sanz MariaTeresa Llop GarciaAngels Mor Olle
A61P 37/08A61P 43/00A61P 37/04A61P 25/28A61P 35/02A61P 27/16A61P 31/06A61P 31/00A61P 29/00A61P 31/20A61P 31/14A61P 35/00A61P 33/06A61P 31/16A61P 31/22A61P 31/04A61P 31/18G01N 33/571G01N 33/56983A61P 11/00A61P 15/18G01N 2469/20G01N 2333/924G01N 2800/347G01N 2500/02C07K 14/20G01N 2800/065A61P 1/04A61P 15/16G01N 33/573A61P 15/02A61P 13/12G01N 2333/20G01N 2800/24C12N 9/2462G01N 2800/2821A61K 38/164G01N 33/56911A61P 1/02A61P 11/16Y02A50/30
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention generally features therapeutic and diagnostic compositions and methods for increasing or decreasing the binding of a lysozyme polypeptide to a Treponema pallidum P17 polypeptide (Tp17) or a Tp17-like polypeptide. More particularly, the invention relates to compositions and methods for detecting, treating, or preventing a pathogen infection or a chronic disorder; and to binding assays using a Tp17-like polypeptide and a lysozyme polypeptide.
Claims
exact text as granted — not AI-modified1 - 62 . (canceled)
63 . A vaccine that increases an immune response in a subject in need thereof, the composition comprising a lysozyme binding polypeptide.
64 . A vaccine that increases an immune response in a subject in need thereof, the composition comprising a lysozyme polypeptide and a polypeptide comprising a lysozyme binding motif.
65 . A method of diagnosing a Herpes Simplex Virus type-2 infection in a subject, the method comprising detecting the presence of a gj protein lysozyme binding motif in a sample from the subject.
67 - 80 . (canceled)Join the waitlist — get patent alerts
Track US2006275317A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.